Exposure to phthalates and phenols during pregnancy and offspring size at birth.
Philippat C, Mortamais M, Chevrier C, Petit C, Calafat AM, Ye X, Silva MJ, Brambilla C, Pin I, Charles MA, Cordier S, Slama R. · 2012
Read Exposure to phthalates and phenols during pregnancy and offspring size at birth. by Philippat C, Mortamais M, Chevrier C, Petit C, Calafat AM, Ye X, Silva MJ, Brambilla C, Pin I, Charles MA, Cordier S, Slama R. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3295340.txt.
Introduction
Philippat and colleagues studied whether chemicals found in everyday products affect the size of newborn boys, reporting in 2012. The chemicals, called phthalates and phenols, appear in plastics, cosmetics, food packaging, and sunscreen. Using two French mother and child study groups, the team measured breakdown products of these chemicals in urine samples taken during pregnancy.
Boys whose mothers had higher levels of two related chlorine based phenols tended to weigh less at birth. A sunscreen ingredient showed the opposite pattern, linking to slightly higher weight and a larger head. A common plastics chemical also linked to a larger head, while phthalate measures showed no steady pattern with birth weight.
Catalog record
| CREATOR | Philippat C, Mortamais M, Chevrier C, Petit C, Calafat AM, Ye X, Silva MJ, Brambilla C, Pin I, Charles MA, Cordier S, Slama R. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | CC0 1.0 Universal |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Exposure to Phthalates and Phenols during Pregnancy and Offspring Size at Birth By Claire Philippat, Marion Mortamais, Cécile Chevrier, Claire Petit, Antonia M. Calafat, Xiaoyun Ye, Manori J. Silva, Christian Brambilla, Isabelle Pin, Marie-Aline Charles, Sylvaine Cordier, Rémy Slama Published in: Environmental Health Perspectives DOI: 10.1289/ehp.1103634 ABSTRACT Background: Data concerning the effects of prenatal exposures to phthalates and phenols on fetal growth are limited in humans. Previous findings suggest possible effects of some phenols on male birth weight. Objective: Our aim was to assess the relationships between prenatal exposures to phthalates and phenols and fetal growth among male newborns. Methods: We conducted a case–control study on male malformations of the genitalia nested in two French mother–child cohorts with recruitment between 2002 and 2006. We measured, in maternal urinary samples collected between 6 and 30 gestational weeks, the concentrations (micrograms per liter) of 9 phenol (n = 191 pregnant women) and 11 phthalate metabolites (n = 287). Weight, length, and head circumference at birth were collected from maternity records. Statistical analyses were corrected for the oversampling of malformation cases. Results: Adjusted birth weight decreased by 77 g [95% confidence interval (CI): –129, –25] and by 49 g (95% CI: –86, –13) in association with a 1-unit increase in ln-transformed 2,4-dichlorophenol (DCP) and 2,5-DCP urinary concentrations, respectively. Benzophenone-3 (BP3) ln-transformed concentrations were positively associated with weight (26 g; 95% CI: –2, 54) and head circumference at birth (0.1 cm; 95% CI: 0.0, 0.2). Head circumference increased by 0.3 cm (95% CI: 0.0, 0.7) in association with a 1-unit increase in ln-transformed BPA concentration. For phthalate metabolites there was no evidence of monotonic associations with birth weight. Conclusions: Consistent with findings of a previous study, we observed evidence of an inverse association of 2,5-DCP and a positive association of BP3 with male birth weight. Diesters of phthalic acid (phthalates) and phenols are found in many consumer products. Low molecular weight (MW) phthalates (MW < 250 g/mol) are used in personal care products (perfumes, cosmetics) or as coating for pharmaceutical products. High MW phthalates (MW > 250 g/mol) tend to be used in polyvinylchloride floor and wall covering, food packaging, and medical devices (Calafat et al. 2006; Hauser and Calafat 2005). Phenols are used in food packaging [bisphenol A, (BPA)], polycarbonates (BPA), cosmetics (parabens), soap [triclosan (TCS)], and sunscreen [benzophenone-3 (BP3)] (Calafat et al. 2008). Precursors of dichlorophenols (DCPs) are used as intermediates in the production of several herbicides or insecticides (Agency for Toxic Substances and Disease Registry 2006). Widespread exposure to phthalates and phenols has been documented for pregnant women in several industrialized countries (Adibi et al. 2008; Braun et al. 2011; Cantonwine et al. 2010; Wolff et al. 2008; Ye et al. 2008, 2009). Some of these compounds can cross the placenta in humans (Balakrishnan et al. 2010; Mose et al. 2007), and phthalates have been detected in cord blood (Latini et al. 2003), amniotic fluid (Huang et al. 2009; Silva et al. 2004), and meconium (Zhang et al. 2009). Little is known about the consequences of prenatal exposures to phthalates and phenols on fetal growth. An American cohort study of 404 mother–infant pairs reported an inverse association for 2,5-DCP maternal urinary concentrations and a positive association for BP3 urinary concentrations with birth weight in male but not in female newborns (Wolff et al. 2008). Our aim was to study the relationships between prenatal exposures to phthalates and phenols and weight, length, and head circumference at birth among male newborns. POPULATION AND METHODS Study population. We conducted a case–control study of male malformations of the genitalia nested in the EDEN (Etude des Déterminants pré et post natals du développement et de la santé de l’Enfant) and PELAGIE mother–child cohorts. These cohorts are described elsewhere (Drouillet et al. 2009; Garlantezec et al. 2009). Briefly, the EDEN cohort consists of 2,002 pregnant women recruited before the end of the 28th gestational week from April 2003 through March 2006 in the obstetrical departments of the University Hospitals of Nancy and Poitiers, France. The PELAGIE cohort consists of 3,421 pregnant women enrolled before 19 weeks of gestation from April 2002 through February 2006 in three districts of Brittany: Ille et Vilaine, Finistère, and Côtes d’Armor, France. The present study includes all of the male newborns with undescended testis or hypospadias (identified at birth by pediatricians; n = 48 in EDEN and 24 in PELAGIE). In addition, three male newborns without congenital malformation of the genitalia (controls) were matched to each case by recruitment center, date of recruitment (± 6 months), day of week (weekend yes/no), and gestational week when the maternal urine sample was collected, for a total of 288 mother–newborn pairs (72 cases and 216 controls). Participants provided informed consent for data and biological sample collection for themselves and their offspring. These cohorts received the approvals of the appropriate ethical committees. The involvement of the Centers for Disease Control and Prevention (CDC) laboratory was limited and determined not to constitute engagement in human subjects research. Outcomes. We extracted from hospital maternity records weight, length, and head circumference assessed at birth. Exposure assessment. Urine was collected between 6 and 19 gestational weeks in the PELAGIE cohort and between 24 and 30 gestational weeks in the EDEN cohort. Assessment of biomarker and creatinine concentrations in maternal urine was done by the National Center for Environmental Health laboratory at the CDC in Atlanta, Georgia, USA (Silva et al. 2007; Ye et al. 2005). We measured the urinary concentrations of 11 phthalate metabolites in samples from all mothers (n = 287; 72 cases and 215 controls because the vial of one control broke during transport to the CDC laboratory). Nine phenols were measured in urine samples collected from mothers in the EDEN cohort only (n = 191; 48 cases and 143 controls) (phenols could not be measured in the PELAGIE cohort because a preservative added to the samples interferes with the assay used). Molar concentrations of four metabolites of di(2-ethylhexyl) phthalate (DEHP) [mono(2-ethylhexyl) phthalate (MEHP); mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP); mono(2-ethyl-5-oxohexyl) phthalate (MEOHP); and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP)] were summed as total DEHP. Concentrations of phthalate metabolites of MW > 250 g/mol and of MW < 250 g/mol were summed as total of high MW phthalates (ΣHMW) and of low MW phthalates (ΣLMW), respectively. Total paraben concentration (ΣPB) was calculated by summing methyl paraben (MP), ethyl paraben (EP), propyl paraben (PP), and butyl paraben (BP) molar concentrations. Monoethyl phthalate (MEP) and monobenzyl phthalate (MBzP) concentrations have been corrected [multiplied by 0.66 (MEP) and 0.72 (MBzP)] because the analytical standards used were of inadequate purity (Calafat AM, personal communication). Statistical analyses. We replaced concentrations below the limit of detection (LOD) by LOD/√–2. We corrected the overrepresentation of congenital abnormalities, induced by the case–control design, using a reweighting approach. We used center-specific weights corresponding to the inverse of the inclusion probability of controls, so as to give cases and controls the same relative weight as in the original cohorts (Richardson et al. 2007). Sensitivity analyses restricted to controls were also conducted. To limit the impact of between-subject variations in urine sampling conditions, we standardized biomarker concentrations using a two-step standardization method based on regression residuals. First, we estimated associations between ln-transformed biomarker concentrations and